-
-
-
-
-
Stem Cell Therapy: 5 Major Challenges
Biotech
Explore the five major challenges in stem cell therapy, including sourcing, immune response, functional heterogeneity, post-transplant viability, and targeted delivery. Learn how these affect clinical outcomes.
-
BioNTech Acquires CureVac in $1.25B mRNA Deal
BioNTech
BioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
-
Bristol Myers Squibb Bets on ACP3 in $1.35B Deal
BMS
Bristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
-
-
-
方山县|
江源县|
安乡县|
晴隆县|
新源县|
安顺市|
广德县|
武义县|
神池县|
马关县|
休宁县|
民乐县|
富宁县|
五原县|
衡山县|
石家庄市|
隆德县|
永泰县|
治多县|
临泉县|
玉树县|
桐城市|
通海县|
榆社县|
西昌市|
临城县|
三门县|
麦盖提县|
信丰县|
永川市|
甘德县|
绍兴市|
韶山市|
兴业县|
长顺县|
沧州市|
襄城县|
台前县|
彭州市|
改则县|
凌源市|